You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 142 No. 12, December 1988 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (25)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Danazol for Children With Immune Thrombocytopenic Purpura

Mark E. Weinblatt, MD; Joseph Kochen, MD; Jorge Ortega, MD

Am J Dis Child. 1988;142(12):1317-1319.


Abstract



• Ten patients with steroid-dependent or refractory immune thrombocytopenic purpura were treated with danazol in an attempt to improve their platelet counts. Nine of the ten children exhibited an excellent initial response to the drug, with five achieving a complete, unmaintained remission. Two others were able to have their prednisone doses tapered with a resultant disappearance of steroid-induced adverse effects. No significant adverse effects of danazol were noted. Danazol seems to be effective in the treatment of children with immune thrombocytopenic purpura and would warrant additional studies to determine its proper role in the management of this common pediatric ailment.

(AJDC 1988;142:1317-1319)



Author Affiliations



From the Department of Pediatrics, Cornell University Medical College, New York, and the Department of Pediatric Hematology, North Shore University Hospital, Manhasset, NY (Drs Weinblatt and Kochen); and the Department of Pediatric Hematology, University of Southern California and Childrens Hospital of Los Angeles (Dr Ortega).


Footnotes



Accepted for publication Aug 15, 1988.

Reprint requests to Department of Pediatric Hematology, North Shore University Hospital, 300 Community Dr, Manhasset, NY 11030 (Dr Weinblatt).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)
Boruchov et al.
Blood 2007;110:3526-3531.
ABSTRACT | FULL TEXT  

Management of Hereditary Angioedema in Pediatric Patients
Farkas et al.
Pediatrics 2007;120:e713-e722.
ABSTRACT | FULL TEXT  

Efficacy of Danazol with Autoimmune Thrombocytopenia
Kim et al.
CLIN APPL THROMB HEMOST 1997;3:251-255.
ABSTRACT  

Treatment of Chronic Idiopathic Thrombocytopenic Purpura with Ascorbate
Cohen et al.
CLIN PEDIATR 1993;32:300-302.
 

Long-Term Danazol Therapy in Autoimmune Thrombocytopenia: Unmaintained Remission and Age-Dependent Response in Women
Ahn et al.
ANN INTERN MED 1989;111:723-729.
ABSTRACT  

DANAZOL FOR IMMUNE THROMBOCYTOPENIC PURPURA
JWatch General 1988;1988:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.